Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation by Minoshima, Satoshi et al.
Alzheimer’s Disease versus Dementia with
Lewy Bodies: Cerebral Metabolic Distinction
with Autopsy Confirmation
Satoshi Minoshima, MD, PhD,1 Norman L. Foster, MD,2 Anders A. F. Sima, MD, PhD,1,4
Kirk A. Frey, MD, PhD,1 Roger L. Albin, MD,2,3 and David E. Kuhl, MD1
Seeking antemortem markers to distinguish Dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD), we exam-
ined brain glucose metabolism of DLB and AD. Eleven DLB patients (7 Lewy body variant of AD [LBVAD] and 4 pure
diffuse Lewy body disease [DLBD]) who had antemortem position emission tomography imaging and autopsy confir-
mation were compared to 10 autopsy-confirmed pure AD patients. In addition, 53 patients with clinically-diagnosed
probable AD, 13 of whom later fulfilled clinical diagnoses of DLB, were examined. Autopsy-confirmed AD and DLB
patients showed significant metabolic reductions involving parietotemporal association, posterior cingulate, and frontal
association cortices. Only DLB patients showed significant metabolic reductions in the occipital cortex, particularly in
the primary visual cortex (LBVAD 223% and DLBD 229% vs AD 28%), which distinguished DLB versus AD with
90% sensitivity and 80% specificity. Multivariate analysis revealed that occipital metabolic changes in DLB were inde-
pendent from those in the adjacent parietotemporal cortices. Analysis of clinically diagnosed probable AD patients
showed a significantly higher frequency of primary visual metabolic reduction among patients who fulfilled later clinical
criteria for DLB. In these patients, occipital hypometabolism preceded some clinical features of DLB. Occipital hypo-
metabolism is a potential antemortem marker to distinguish DLB versus AD.
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Lewy bodies are associated historically with Parkinson’s
disease (PD) and are found in brainstem nuclei such as
the substantia nigra and locus ceruleus.1 Similar inclu-
sion bodies have been identified in the cortices of de-
mented patients.2,3 With the development of immuno-
cytochemical staining,4,5 there is increasing recognition
of cortical Lewy bodies in dementia patients. Accord-
ing to a recent report, dementia with Lewy bodies
(DLB) is considered to be the second most common
cause of neurodegenerative dementing disorders follow-
ing Alzheimer’s disease (AD).6 Distinction between
these diseases becomes important from the viewpoint
of pharmacological treatment and outcome evaluation.
There are suggestions of differential responses to cho-
linesterase inhibitor treatment7 and prognosis between
the two diseases.8 Adverse responses to certain drug
treatments, such as severe and potentially fatal neuro-
leptic sensitivity, are reported to occur more often in
DLB.9 Antemortem differentiation will permit better
prospective selection of more uniform pure AD or
DLB patient populations for clinical and research in-
vestigations and pharmacological trials. There are con-
sensus reports on the clinical and pathologic diagnostic
criteria for DLB,6 but the accuracy of the clinical di-
agnostic criteria has been debated.10,11 There are on-
going efforts to establish accurate and objective meth-
ods for antemortem differential diagnosis of DLB.
Albin and colleagues reported an occipital metabolic
reduction with autopsy-confirmed Lewy body disease
using positron emission tomography (PET).12 Occipi-
tal metabolic reduction was observed also in clinically-
diagnosed PD with dementia.13 These findings have
been confirmed independently.14,15 In contrast, inves-
tigators have observed relatively preserved occipital me-
tabolism with AD.16,17 These two observations suggest
that occipital metabolic reduction may be a metabolic
signature specific to DLB and can be used to distin-
guish the two diseases antemortem. To test this hy-
pothesis, we compared cerebral metabolic patterns of
autopsy-confirmed patients with DLB and pure AD
who had antemortem PET imaging. To extend the
analysis, we also examined occipital metabolism in a
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large number of clinically-diagnosed AD, some of




In the first part of the study, patients with pure AD or DLB
were identified between 1990 and 1996 from an autopsy da-
tabase established at the Michigan Alzheimer’s Disease Re-
search Center. Postmortem diagnosis of AD was made ac-
cording to the age-specific quantitative criteria established by
Khachaturian.18 For DLB diagnosis, at least three Lewy bod-
ies per 320 field had to be present in four fields on
ubiquitin-stained sections in three of the four most com-
monly affected areas,19 namely transentorhinal cortex, ante-
rior cingulate cortex, amygdala, and insular cortex.12,20 For
Lewy body variant of Alzheimer’s disease (LBVAD), both
sets of the above criteria had to be met. Ten patients with
pure AD, 7 with LBVAD, and 4 with pure diffuse Lewy
body disease (DLBD) had participated in glucose metabolic
PET imaging research antemortem at the Division of Nu-
clear Medicine, The University of Michigan. At the time of
PET scan, all pure AD patients had a clinical diagnosis of
probable AD based on NINCDS/ADRDA criteria.21 Among
LBVAD patients, 4 patients carried a clinical diagnosis of
probable AD, 2 patients had probable AD with extrapyrami-
dal signs, and 1 patient had Parkinson’s disease with demen-
tia. Among DLBD patients, 1 patient had a clinical diagnosis
of probable AD, 1 patient had probable AD with extrapyra-
midal signs, and 2 patients had Parkinson’s disease with de-
mentia. A mean Mini-Mental State Examination (MMSE)
score22 and clinical dementia rating (CDR)23 were measured
at the time of PET imaging (Table 1). Differences in means
for age of onset, age, MMSE score, and CDR at the time of
PET scan, and interval between PET and autopsy among
AD, LBVAD, and DLBD were not significant (Analysis of
Variance, p . 0.05). Ten age-similar normal controls (6 fe-
males, mean age 68 6 6 years and mean MMSE scores of
29 6 1), free from neurological abnormalities on the day of
PET scan, were included for comparison.
In the second part of the study, cerebral glucose metabolic
PET image sets of 66 probable AD patients who were re-
cruited between 1989 and 1992 from the Cognitive Disor-
ders Clinic, The University of Michigan, for ongoing re-
search protocols were analyzed retrospectively. All patients
had a clinical diagnosis of probable AD at the time of PET
scan. Eleven patients who later had autopsy confirmation of
the diagnosis were included in the first part of the study and
were excluded from this analysis. One patient showed mild
extrapyramidal symptoms, and one patient had experienced
possible visual hallucination at the time of the recruitment to
PET studies. Exclusion of these patients resulted in 53 pa-
tients (see Table 1). Clinical followup occurred at 5 to 13
month intervals, and neurological and neuropsychological
evaluations were repeated. Using their clinically documented
medical information, these patients were reclassified retro-
spectively to probable DLB, possible DLB, or remained
probable AD based on recently proposed clinical diagnostic
criteria for DLB.6 Among the 53 patients, 4 and 9 patients
were classified as probable and possible DLB, respectively,
and 40 patients remained classified as probable AD. Differ-
ences in means for age of onset, age, mean MMSE score, and
CDR at the time of PET scan among probable DLB, possi-
ble DLB, and probable AD were not significant (Analysis of
Variance, p . 0.05).
PET Cerebral Glucose Metabolic Measurement
Glucose metabolic PET images were obtained using a Sie-
mens ECAT scanner (model 931/08-12, CTI, Knoxville,
TN) starting at 30 minutes following intravenous injection
of 10mCi (370MBq) of [18F]-2-fluoro-2-deoxy-D-glucose in
a dimly lit room with patient’s eyes open.24 The protocol
was approved by the Institutional Review Board of the Uni-
versity of Michigan Medical School.
Data Analysis
PET image analysis was performed using automated methods
to minimize observer biases and to improve reproducibility
of results.25,26 Briefly, each reconstructed image set was
warped to the common stereotactic coordinate system,27,28
and gray matter activities were extracted to predefined sur-
face pixels using a three-dimensional stereotactic surface pro-










Alzheimer’s disease 9/1 66 6 7 69 6 6 14 6 6 1.7 6 1.0 3.1 6 1.0
Lewy body variant of Alzheimer’s
disease
3/4 67 6 7 72 6 6 11 6 7 2.0 6 1.0 3.2 6 2.0
Pure diffuse Lewy body disease 3/1 70 6 6 71 6 8 18 6 13 1.7 6 1.2 3.4 6 2.6
Clinically diagnosed
Probable Alzheimer’s disease 16/24 65 6 8 69 6 8 16 6 6 1.4 6 0.7 —
Probable dementia with Lewy bodies 3/1 58 6 7 66 6 3 11 6 6 1.5 6 1.0 —
Possible dementia with Lewy bodies 4/5 61 6 9 65 6 8 17 6 5 1.1 6 0.4 —
aMMSE and CDR were measured at the time of PET imaging. Mean 6 standard deviation.
M/F 5 male and female subjects; PET 5 position emission tomography; MMSE 5 Mini-Mental State Examination scores22; CDR 5 clinical
dementia rating.23
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jection technique (3D-SSP).25,26 To increase the sensitivity
of the analysis and to obviate invasive arterial blood sam-
pling, data sets were normalized to the pontine activity in
which glucose metabolic activity is known to be preserved
relatively in AD17 and DLB.12,13
Nine cortical regions of interest (ROI) were predefined for
each hemisphere based on the stereotactic brain atlas27 as fol-
lows: lateral parietal association (including Brodmann’s cor-
tical areas, BA 5, 7, 39, and 40); lateral temporal association
(BA 21, 22, 37, and 38); lateral frontal association (BA 6,
8–11, and 44–47); lateral occipital association (BA 18 and
19); mesiotemporal (BA 27, 28, and 34); posterior cingulate
(BA 23 and 31); anterior cingulate (BA 24 and 32); primary
visual (BA 17); and primary sensorimotor (BA 1–4) cortices.
In addition, three subcortical ROIs were predefined in the
thalamus, striatum, and cerebellar hemispheres. Metabolic
activities were averaged between hemispheres, but metabolic
asymmetry was examined also in the occipital cortices by an
asymmetry index of (right 2 left)/(right 1 left).
The Analysis of Variance followed by post-hoc univariate
F tests and Bonferroni correction for multiple comparisons
were performed to examine group differences between nor-
mal controls versus AD, LBVAD, and DLBD as well as be-
tween AD versus LBVAD and DLBD. Receiver-operating
characteristics (ROC) analysis29 was performed to examine
the discriminatory accuracy of glucose metabolic PET imag-
ing between DLB and AD. Correlation between regional
metabolic reductions and MMSE scores was also examined
in DLB patients, and the statistical significance was esti-
mated with Bonferroni multiple comparison adjustment.
Pixel-by-pixel comparisons of metabolic activities were
performed to elucidate the metabolic patterns of AD and
DLB over the entire brain. Two-sample t statistic values
(converted to Z) were calculated between AD and DLB at
each pixel, and the extent and significance of metabolic re-
duction in each disease category were assessed on the Z score
maps with an approximate statistical Z threshold of 4.53.30
To characterize the nature of regional metabolic reduction
further, image-based principal components analysis31,32 was
applied on the autopsy-confirmed, DLB (LBVAD 1 DLBD)
data. This analysis revealed intercorrelated patterns of re-
gional metabolic changes occurring in DLB brains.
Retrospective analysis of 53 probable AD patients com-
pared the frequency of metabolic reduction in the primary
visual cortex between patients with clinically-diagnosed DLB
and probable AD (k2 test) using Z-scores defined as (normal
mean 2 patient value)/(normal standard deviation). We also
examined the time interval between PET findings and onset
of DLB symptoms.
Results
Autopsy-confirmed AD patients had significant meta-
bolic reductions in the lateral parietal, temporal, and
frontal association cortices and posterior cingulate cor-
tex (Table 2, A–N). Metabolic reductions in the pri-
mary visual and sensorimotor cortices as well as sub-
cortical structures were relatively mild and were not
significant. The region-specific pattern of metabolic re-
duction in autopsy-confirmed AD was clearly demon-
strated on a statistical map (Figure 1, AD). These find-
Table 2. Energy Metabolism in Alzheimer’s Disease, Lewy Body Variant of Alzheimer’s Disease, and
Pure Diffuse Lewy Body Disease a









(n 5 4) A–Nb L–Nc D–Nd L–Ae D–Af
Association cortex
Frontal 1.40 6 0.14 1.12 6 0.10 1.11 6 0.18 1.14 6 0.23 220%g 221%g 219% 21% 2%
Parietal 1.35 6 0.13 0.90 6 0.09 0.88 6 0.15 0.94 6 0.16 233%h 235%h 230%h 22% 5%
Temporal 1.25 6 0.09 0.91 6 0.05 0.94 6 0.09 1.02 6 0.15 227%h 225%h 218%g 3% 13%
Occipital 1.31 6 0.08 1.10 6 0.15 0.97 6 0.15 0.95 6 0.11 216% 226%h 228%h 212% 213%
Limbic cortex
Posterior cingulate 1.41 6 0.13 1.08 6 0.13 1.00 6 0.16 1.03 6 0.19 224%h 229%h 227%h 27% 24%
Anterior cingulate 1.20 6 0.11 1.00 6 0.11 1.02 6 0.13 1.02 6 0.17 217% 215% 215% 3% 3%
Mesiotemporal 0.97 6 0.06 0.89 6 0.06 0.86 6 0.07 0.92 6 0.08 28% 211% 25% 23% 4%
Primary cortex
Sensorimotor 1.47 6 0.15 1.28 6 0.12 1.29 6 0.14 1.27 6 0.22 213% 212% 214% 1% 21%
Visual 1.49 6 0.09 1.37 6 0.13 1.14 6 0.13 1.05 6 0.16 28% 223%h 229%h 217%g 223%g
Subcortex
Thalamus 1.63 6 0.15 1.47 6 0.09 1.45 6 0.14 1.43 6 0.22 210% 211% 212% 21% 23%
Striatum 1.47 6 0.16 1.36 6 0.11 1.33 6 0.15 1.45 6 0.19 27% 29% 21% 22% 7%
Cerebellum 1.24 6 0.03 1.16 6 0.05 1.14 6 0.09 1.22 6 0.15 26% 28% 22% 22% 4%






gp , 0.05 (adjusted for multiple comparisons).
hp , 0.005 (adjusted for multiple comparisons).
N 5 normal; AD(A) 5 pure Alzheimer’s disease; LBVAD(L) 5 Lewy body variant of AD; DLBD(D) 5 pure diffuse Lewy body disease.
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ings are consistent with previous imaging studies of
clinically-diagnosed AD.
DLB patients showed significant metabolic reductions
in the lateral association and posterior cingulate cortices,
similar to AD, but distinct in the significant reduction
found in the occipital lobe particularly primary visual
cortex (see Table 2, L–N and D–N). Both LBVAD and
DLBD patients showed severe metabolic reduction in
the occipital lobe. Metabolic reduction in the visual cor-
tex in LBVAD and DLBD was significantly greater than
that in AD (see Table 2, L–A and D–A). Statistical
maps confirmed the marked similarity of metabolic re-
ductions in the lateral parietotemporal and frontal asso-
ciation cortices between AD and DLB (both LBVAD
and DLBD), but distinct differences in the lateral occip-
ital and primary visual cortices (see Fig 1, DLB,
LBVAD, and DLBD). Individual analysis of hemi-
spheric averaged metabolic activities in the primary vi-
sual cortex showed 8 of 11 patients with DLB had a
metabolic reduction greater than the most severe reduc-
tion found in AD patients (Fig 2).
There was a mild metabolic asymmetry in the occip-
ital lobe. Mean asymmetry indices of the occipital lat-
eral cortex were 3% in AD (range 0–11%), 4% in
DLB (0–9%) as compared to 1% in normal controls
(0–3%). Metabolic asymmetry in the primary visual
cortex was present, but less than that seen in the oc-
cipital lateral association cortex (mean 2%, range
0–5% in all categories). Based on the lower hemi-
spheric value of metabolic activities in the primary vi-
sual cortices, ROC analysis indicated sensitivities and
specificities of 90% and 80% at Z 5 22.4, 87% and
85% at Z 5 22.5, and 83% and 90% at Z 5 22.6,
respectively, when discriminating DLB and AD.
Multivariate analysis of regional glucose metabolism
in DLB brains revealed that regional metabolic changes
did not occur randomly, but in a regionally coordi-
nated manner. Metabolic changes within the occipital
lobe including primary visual and association cortices
were intercorrelated with each other (Fig 3, PC3, 10%
of metabolic variances in DLB brains explained by this
component). However, these changes did not correlate
with changes within the anterior component (frontal
association cortex—anterior cingulate cortex—caudate
nucleus) (see Fig 3, PC1, 49%) or those within the
posterior component (parietotemporal association cor-
tices—posterior cingulate cortex) (see Fig 3, PC2,
24%). These findings indicate that distinct pathophys-
iological processes may account for the metabolic ab-
normalities seen in the occipital lobe of DLB. Correla-
tion analysis in DLB patients demonstrated significant
correlation between regional metabolic reductions and
MMSE scores in the parietal association cortex (r 5
0.81, p , 0.05 after multiple comparison adjustment),
temporal association cortex (r 5 0.81, p , 0.05), pos-
terior cingulate cortex (r 5 0.75, p , 0.05), and fron-
tal association cortex (r 5 0.75, p , 0.05). Metabolic
reductions in the visual cortex or occipital association
cortex, however, did not show a significant correlation
(r 5 0.32 and r 5 0.58, respectively, both p . 0.05).
These findings indicate, again, that the occipital dys-
function in DLB is distinct from the metabolic abnor-
malities in other association cortices that correlate with
dementia severity.
Out of 53 patients with an initial clinical diagnosis
of probable AD, 13 patients (25%) fulfilled the clinical
diagnostic criteria for probable or possible DLB during
the course of clinical followup. The diagnoses were
based on Parkinsonian symptoms in 13 patients, visual
hallucination in 4 patients, and cognitive fluctuation in
1 patient. When examining metabolic reduction in the
primary visual cortex using Z 5 22.0 as a threshold
(exceeding this threshold by chance is 2%), only 5 of
40 probable AD patients (13%) showed metabolic re-
duction in the visual cortex. In contrast, 5 of 9 possible
DLB patients (56%) and 3 of 4 probable DLB patients
(75%) showed metabolic reduction in the visual cortex.
These findings indicated a significantly higher inci-
dence of metabolic reduction in the visual cortex with
clinically-diagnosed DLB as compared to probable AD
(k2 test, p , 0.01). Using a more rigorous discrimina-
tive threshold of Z 5 22.5, estimated from autopsy-
proven cases as the optimal cutoff (exceeding this
threshold by chance is 0.6%), 2 of 40 probable AD
patients (5%) showed metabolic reduction in the pri-
mary visual cortex as compared to 2 of 9 possible DLB
patients (22%) and 3 of 4 probable DLB patients
(75%). Again, the incidence of metabolic reduction in
the primary visual cortex with DLB was significantly
greater than that in AD (k2 test, p , 0.01). Despite
known limitations in accuracy of retrospective clinical
diagnosis for DLB, the above cutoff thresholds yielded
specificity 88% and sensitivity 62% (Z 5 22.0) and
specificity 95% and sensitivity 38% (Z 5 22.5), re-
spectively, for the discrimination of clinically diagnosed
AD versus possible and probable DLB.
All 53 patients were recruited initially as probable
AD without extrapyramidal signs, visual hallucination,
or cognitive fluctuation, some of whom later developed
additional DLB symptoms during the course of the
disease. Among clinically-reclassified DLB patients
showing metabolic reduction in the primary visual cor-
tex (Z threshold 22.0), mean duration between PET
imaging performed at the time of the diagnosis of
‘probable AD’ and onset of DLB symptoms were 41
months for Parkinsonism (21–78 months), 29 months
for visual hallucination (6–50 months), and 51 months
for cognitive fluctuation.
Discussion
This study revealed comparable degrees of metabolic
reduction in the parietotemporal and frontal associa-
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tion cortices in both autopsy-confirmed DLB and AD,
but only DLB showed severe metabolic reductions in
the occipital lobe. These findings were similar for both
LBVAD and DLBD. Occipital metabolic changes,
however, did not correlate with parietotemporal
changes in DLB, suggesting impairment of distinct
neuronal systems. Retrospective analysis of clinically-
diagnosed probable AD patients showed that 25% ful-
filled consensus criteria for probable or possible DLB
in their clinical courses. These patients had a signifi-
cantly higher incidence of metabolic reduction in the
occipital lobe that preceded the occurrence of some
DLB symptoms. These two separate analyses indicate
clearly that metabolic reduction in the occipital lobe,
particularly the primary visual cortex, is a metabolic
signature of DLB. Investigations of distinct metabolic
patterns between AD, LBVAD, and DLBD are possi-
ble only by means of postmortem confirmation of the
diagnoses since there currently is no perfect clinical cri-
teria to distinguish these interrelated diseases.33,34
Fig 1. Cerebral metabolic reduction in autopsy-confirmed Alz-
heimer’s disease (AD), dementia with Lewy bodies (DLB),
Lewy body variant of Alzheimer’s disease (LBVAD), and pure
diffuse Lewy body disease (DLBD). DLB represents pooled
data of LBVAD and DLBD. Color coding represents statistical
significance (Z-score) of regional metabolic reduction in com-
parison to age-similar normal controls. The right lateral
(RT.LAT), left lateral (LT.LAT), right medial (RT.MED),
and left medial (LT.MED) views of the brain are presented
(see reference anatomic images, REF). Red represents more
significant metabolic reduction. In AD and DLB, there is
significant metabolic reduction in the lateral association corti-
ces, but sparing the primary sensorimotor cortex in between
frontal and parietal association cortices (RT.LAT and
LT.MED). On the medial views of the brain (RT.MED and
LT.MED), there is sparing of glucose metabolism in the oc-
cipital cortex in AD (arrows), but significant reduction is seen
in DLB, LBVAD, and DLBD.
Fig 3. Intercorrelation of regional metabolic changes in DLB
as revealed by multivariate correlational analysis. The same
views of the brain as Figure 1 are shown. Color coding repre-
sents correlation coefficients with latent components (PC1 to
PC3). The first component, PC1 represents intercorrelated
metabolic changes within the anterior component (frontal asso-
ciation cortex—anterior cingualte cortex—caudate nucleus).
The second component PC2 represents the posterior component
(parietotemporal association cortices—posterior cingulate cor-
tex). Occipital changes, PC3, are distinct from these two com-
ponents, indicating the involvement of a distinct system in the
pathophysiology of occipital metabolic abnormalities in DLB.
Š Fig 2. Metabolic reduction in the primary visual cortex in
individual patients of autopsy-confirmed AD, LBVAD, and
DLBD. Metabolic activities of right and left hemispheres are
averaged prior to the analysis. Metabolic reduction is expressed
as Z-scores in comparison to age-similar normal controls.
LBVAD and DLBD show greater metabolic reduction in the
primary visual cortex as compared to AD.
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Occipital metabolic (or coupled bloodflow) reduc-
tion in PD with dementia has been observed previ-
ously,35,36 but not discussed critically. Recent inves-
tigations, employing sophisticated image analysis,
consistently indicated occipital metabolic reductions, in
addition to extensive parietotemporal and frontal asso-
ciation metabolic abnormalities, in clinically-diagnosed
Parkinson’s disease with dementia, clinically-diagnosed
DLB, and autopsy-confirmed DLB.12–15,37,38 Given
that a substantial population of Parkinson’s disease
with dementia is reported to have cortical Lewy bod-
ies,39 occipital metabolic reduction appears to be a bi-
ological marker found consistently in patients with
Lewy body disease.
What pathophysiology could account for the occip-
ital metabolic reduction in DLB? In DLBD, the den-
sity of Lewy bodies was reported to be the lowest in
the occipital cortex.19,40 Although precise comparisons
between antemortem metabolic changes and postmor-
tem pathological findings are difficult due to the time
interval, the expression of Lewy bodies in DLB brains
does not appear to correlate with the distribution of
metabolic changes. This discordance between meta-
bolic and classical pathologic changes, however, is not
unique to DLB.41 In AD, classical pathologic changes
occur initially in the transentorhinal cortex.42 In con-
trast, early metabolic changes occur in the posterior
cingulate cortex and lateral association cortices,24
which correlate more closely with synaptic alterations
revealed by immunocytochemical analysis.43 Multivar-
iate analysis showed that occipital metabolic abnormal-
ities were not merely an extension of parietotemporal
pathology (see Fig 2), indicating an impairment of dis-
tinct neuronal systems. A similar but milder metabolic
reduction in the occipital lobe was observed also in
Parkinson’s disease without dementia.44–46 This may
or may not indicate preclinical evidence of Lewy body
dementia. However, our previous study demonstrated
that occipital reduction correlated with nigrostriatal
dopaminergic functions,46 and indicated a possible
pathophysiological relationship in impaired saccade
and visual attentional systems.47 Metabolic reduction
in the visual cortex also coincides clinically with a high
prevalence of visual hallucinations in DLB.6 Abnormal-
ities in primary visual processing as evidenced by met-
abolic reduction in DLB and PD, may cause a ‘release’
of higher visual association cortices and result in visual
hallucinations.48 Alternatively, visual hallucinations
might be caused by neurochemical changes outside of
the primary visual system.49 Further pathophysiological
investigation to account for occipital metabolic reduc-
tion in DLB is warranted.
One autopsy study showed 36% of clinically diag-
nosed and pathologically confirmed AD patients had
cortical and subcortical Lewy bodies.50 This frequency
was similar to our retrospective analysis of probable
AD patients who also fulfilled the consensus diagnosis
of DLB (25%), although a detailed metabolic analysis
of clinically-diagnosed DLB patients suffers from un-
certainty of clinical diagnosis and delay until patho-
logic confirmation. Interestingly, a majority of proba-
ble AD patients who later fulfilled the consensus
diagnostic criteria of DLB did not have clinical symp-
toms of DLB other than dementia at the time of PET
imaging. Glucose metabolic abnormalities preceding
clinical symptoms are known to occur with Hunting-
ton’s disease51 and AD.24,52 Similar phenomena may
occur in occipital metabolism of DLB as seen in this
study. Further follow up of the patients involved in our
retrospective analysis and postmortem diagnosis will
confirm the accuracy of metabolic imaging in the early
detection of DLB.
Consistent observation of a metabolic reduction in
the medial occipital cortex in DLB suggests the use of
functional brain imaging as a potential clinical diagnos-
tic aid to differentiate DLB from AD. The sensitivity
in discriminating DLB and AD in the current study
was greater than that with clinical diagnostic criteria
applied retrospectively to the data from medical
charts.33 The sensitivity is also greater than a carefully
designed prospective clinicopathological correlation
study,10 but direct comparison is difficult due to dif-
ferent populations of patients involved in these studies.
The specificity of the current study was comparable to
those based on retrospective clinical diagnoses, but a
carefully designed clinical examination for DLB may
outperform in specificity.10 Diagnostic accuracy can be
adjusted based on a cutoff threshold applied, and can
be optimized for the desired purpose of the test (such
as maximizing specificity by a higher threshold for the
confirmatory identification of DLB). It is also impor-
tant to note that diagnosis using functional brain im-
aging can be performed in the initial clinical visit with-
out followup for diagnostic purposes. Similar
diagnostic information may be also obtained with more
widely available perfusion SPECT imaging.14 An alter-
native approach would be to use dopaminergic imag-
ing. Dopaminergic changes in the striatum showed dif-
ferential rostocaudal distributions between DLB versus
PD and varying degrees of severity between DLB and
PD versus AD.53 These findings have a potential for
the in vivo imaging differentiation of DLB versus
AD.54 One significant advantage of glucose metabolic
(or perfusion) imaging, however, is the capacity to dif-
ferentiate other dementing disorders, such as fronto-
temporal lobe dementia and vascular dementia,55 in a
single study. Metabolic imaging fulfills many features
of a proposed biomarker for AD.56 The accurate ante-
mortem differential diagnosis of interrelated dementing
disorders will help select patients who can benefit from
drugs specific to diseases and develop drug trials by
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permitting an accurate selection of patients with more
uniform pathology.
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